IRIS Accounts Production v25.1.3.33 06267170 Board of Directors 1.12.23 30.11.24 30.11.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh062671702023-11-30062671702024-11-30062671702023-12-012024-11-30062671702022-11-30062671702022-12-012023-11-30062671702023-11-3006267170ns14:PoundSterling2023-12-012024-11-3006267170ns10:Director12023-12-012024-11-3006267170ns10:PrivateLimitedCompanyLtd2023-12-012024-11-3006267170ns10:SmallEntities2023-12-012024-11-3006267170ns10:AuditExempt-NoAccountantsReport2023-12-012024-11-3006267170ns10:SmallCompaniesRegimeForDirectorsReport2023-12-012024-11-3006267170ns10:SmallCompaniesRegimeForAccounts2023-12-012024-11-3006267170ns10:FullAccounts2023-12-012024-11-3006267170ns10:Director22023-12-012024-11-3006267170ns10:Director32023-12-012024-11-3006267170ns10:RegisteredOffice2023-12-012024-11-3006267170ns5:CurrentFinancialInstruments2024-11-3006267170ns5:CurrentFinancialInstruments2023-11-3006267170ns5:Non-currentFinancialInstruments2024-11-3006267170ns5:Non-currentFinancialInstruments2023-11-3006267170ns5:ShareCapital2024-11-3006267170ns5:ShareCapital2023-11-3006267170ns5:SharePremium2024-11-3006267170ns5:SharePremium2023-11-3006267170ns5:CapitalRedemptionReserve2024-11-3006267170ns5:CapitalRedemptionReserve2023-11-3006267170ns5:RetainedEarningsAccumulatedLosses2024-11-3006267170ns5:RetainedEarningsAccumulatedLosses2023-11-3006267170ns5:PlantMachinery2023-12-012024-11-3006267170ns5:FurnitureFittings2023-12-012024-11-3006267170ns5:PlantMachinery2023-11-3006267170ns5:FurnitureFittings2023-11-3006267170ns5:PlantMachinery2024-11-3006267170ns5:FurnitureFittings2024-11-3006267170ns5:PlantMachinery2023-11-3006267170ns5:FurnitureFittings2023-11-3006267170ns5:WithinOneYearns5:CurrentFinancialInstruments2024-11-3006267170ns5:WithinOneYearns5:CurrentFinancialInstruments2023-11-3006267170ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2024-11-3006267170ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2023-11-3006267170ns5:Non-currentFinancialInstrumentsns5:MoreThanFiveYears2024-11-3006267170ns5:Non-currentFinancialInstrumentsns5:MoreThanFiveYears2023-11-3006267170ns5:AcceleratedTaxDepreciationDeferredTax2024-11-3006267170ns5:AcceleratedTaxDepreciationDeferredTax2023-11-3006267170ns5:DeferredTaxation2023-11-3006267170ns5:DeferredTaxation2023-12-012024-11-3006267170ns5:DeferredTaxation2024-11-3006267170ns5:RetainedEarningsAccumulatedLosses2023-11-3006267170ns5:SharePremium2023-11-3006267170ns5:CapitalRedemptionReserve2023-11-3006267170ns5:RetainedEarningsAccumulatedLosses2023-12-012024-11-3006267170ns5:RetainedEarningsAccumulatedLosses2022-12-012023-11-30
REGISTERED NUMBER: 06267170















FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 NOVEMBER 2024

FOR

DENOVO HEALTHCARE LTD

DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


DENOVO HEALTHCARE LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 30 NOVEMBER 2024







DIRECTORS: Mr M A G Gibson
Mr N J Talbot
Mr R T G Gibson





REGISTERED OFFICE: 6A Wedmore Road
Cheddar
Somerset
BS27 3EB





REGISTERED NUMBER: 06267170





ACCOUNTANTS: Lowson Ward
Chartered Accountants
292 Wake Green Road
Birmingham
B13 9QP

DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)

BALANCE SHEET
30 NOVEMBER 2024

30/11/24 30/11/23
Notes £    £   
FIXED ASSETS
Tangible assets 3 20,321 21,200

CURRENT ASSETS
Stocks 144,914 149,398
Debtors 4 454,300 441,821
Cash at bank 129,682 82,684
728,896 673,903
CREDITORS
Amounts falling due within one year 5 (513,209 ) (449,393 )
NET CURRENT ASSETS 215,687 224,510
TOTAL ASSETS LESS CURRENT
LIABILITIES

236,008

245,710

CREDITORS
Amounts falling due after more than
one year

6

(35,417

)

(60,417

)

PROVISIONS FOR LIABILITIES 7 (5,080 ) (5,300 )
NET ASSETS 195,511 179,993

DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)

BALANCE SHEET - continued
30 NOVEMBER 2024

30/11/24 30/11/23
Notes £    £   
CAPITAL AND RESERVES
Called up share capital 60 60
Share premium 8 61,939 61,939
Capital redemption reserve 8 (138,460 ) (138,460 )
Retained earnings 8 271,972 256,454
SHAREHOLDERS' FUNDS 9 195,511 179,993

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 28 May 2025 and were signed on its behalf by:





Mr N J Talbot - Director


DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2024

1. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Equipment - 33% on reducing balance
Premises improvements - straight line over lease term

All fixed assets are initially recorded at cost.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2024

1. ACCOUNTING POLICIES - continued

Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability.

Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

2. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 12 (2023 - 11 ) .

3. TANGIBLE FIXED ASSETS
Premises
Equipment improvements Totals
£    £    £   
COST
At 1 December 2023 79,229 50,280 129,509
Additions 7,749 - 7,749
At 30 November 2024 86,978 50,280 137,258
DEPRECIATION
At 1 December 2023 61,459 46,850 108,309
Charge for year 7,381 1,247 8,628
At 30 November 2024 68,840 48,097 116,937
NET BOOK VALUE
At 30 November 2024 18,138 2,183 20,321
At 30 November 2023 17,770 3,430 21,200

DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2024

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30/11/24 30/11/23
£    £   
Trade debtors 384,303 361,072
Other debtors 60,000 60,000
Prepayments 9,997 20,749
454,300 441,821

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30/11/24 30/11/23
£    £   
Trade creditors 370,628 294,398
Corporation tax 52,405 69,494
PAYE and NIC 5,182 8,669
VAT 71,142 67,856
Other creditors 4,191 3,990
Pension 1,013 1,157
Directors' current accounts 3,354 1,232
Accruals and deferred income 5,294 2,597
513,209 449,393

6. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
30/11/24 30/11/23
£    £   
Bank loans - 1-2 years 25,000 25,000
Other loans - 2-5 years 10,417 35,417
35,417 60,417

7. PROVISIONS FOR LIABILITIES
30/11/24 30/11/23
£    £   
Deferred tax
Accelerated capital allowances 5,080 5,300

Deferred
tax
£   
Balance at 1 December 2023 5,300
Provided during year (220 )
Balance at 30 November 2024 5,080

DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2024

8. RESERVES
Capital
Retained Share redemption
earnings premium reserve Totals
£    £    £    £   

At 1 December 2023 256,454 61,939 (138,460 ) 179,933
Profit for the year 193,518 - - 193,518
Dividends (178,000 ) - - (178,000 )
At 30 November 2024 271,972 61,939 (138,460 ) 195,451

9. RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS
30/11/24 30/11/23
£    £   
Profit for the financial year 193,518 168,920
Dividends (178,000 ) (105,700 )
15,518 63,220
Opening shareholders' funds - 116,773
Net addition to shareholders' funds 15,518 179,993
Opening shareholders' funds 179,993 -
Closing shareholders' funds 195,511 179,993